Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment

BackgroundRepeated radioiodine (131I) treatment (RT) are commonly performed in patients with 131I-avid distant metastatic differentiated thyroid cancer (DM-DTC), but more precise indications remain indeterminate. This prospective study was conducted to explore predictors for biochemical response (BR...

Full description

Bibliographic Details
Main Authors:	Ri Sa, Lin Cheng, Yuchen Jin, Hao Fu, Yan Shen, Libo Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Endocrinology
Subjects:	thyroid cancer radioiodine target/background ratio thyroglobulin biochemical response
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2020.587315/full

Similar Items

Successful pregnancy without disease progression of radioiodine refractory papillary thyroid carcinoma: a case report
by: Yuchen Jin, et al.
Published: (2017-11-01)

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
by: Lv RB, et al.
Published: (2017-08-01)

Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia
by: Ivan I. Dedov, et al.
Published: (2018-12-01)

Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
by: Congcong Wang, et al.
Published: (2021-05-01)

CYTOLOGICAL CHARACTERISTICS OF POSTOPERATIVE METASTASES OF PAPILLARY THYROID CANCER DURING THE DEVELOPMENT OF SECONDARY RADIOIODINE REFRACTORINESS
by: Anna Zelinskaya, et al.
Published: (2020-01-01)

Evaluation of a Number of Blood Biochemical Markers after Radioiodine Therapy in Papillary Thyroid Cancer Patients
by: Mehrossadat Alavi, et al.
Published: (2017-04-01)

Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience
by: David J Lubin, et al.
Published: (2021-01-01)

Is 131I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy?
by: Pedro Weslley Rosario, et al.

Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators
by: Zhong-Ling Qiu, et al.
Published: (2020-01-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Postoperative Stimulated Thyroglobulin Level and Recurrence Risk Stratification in Differentiated Thyroid Cancer
by: Xue Yang, et al.
Published: (2015-01-01)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma
by: Arwa Alsaud, et al.
Published: (2020-03-01)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
by: Dario Tumino, et al.
Published: (2017-11-01)

Evaluation of Thyroid to Background Ratios in Hyperthyroid Cats
by: Bettencourt, Ann Elizabeth
Published: (2014)

Value of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in staging of patients with differentiated thyroid cancer after thyroidectomy during the first course of radioiodine therapy
by: T. M. Geliashvili, et al.
Published: (2021-01-01)

Radioiodine-resistant metastases of well-differentiated thyroid cancer, analysis of tumor characteristics and primary surgical intervention
by: M. V. Ostafiychuk, et al.
Published: (2021-10-01)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
by: Nishikant Avinash Damle, et al.
Published: (2012-01-01)

Clinical significance of thyroglobulin autoantibodies enhancement in patients with differentiated thyroid cancer after thyroidectomy and radioiodine therapy
Published: (2013-09-01)

Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases
by: Jochen Hammes, et al.
Published: (2018-12-01)

Sudden Development of Subcutaneous Nodules Shortly after Radioiodine Treatment for Thyroid Cancer Caused by Self-Limiting Sarcoidosis
by: Wael Zaher, et al.
Published: (2020-05-01)

Restaging of differentiated thyroid carcinoma with SPECT/CT after radioiodine therapy
by: Mariya Alekseevna Karalkina, et al.
Published: (2015-07-01)

Serum markers for recurrence in patients with differentiated thyroid cancer after combined treatment and the retreatment results
by: Dmitriy Kirillovich Fomin, et al.
Published: (2015-02-01)

Comparison of three methods used for measurement of radioiodine fixation in thyroid gland of mice
by: Jeremić Marija Ž., et al.
Published: (2013-01-01)

A rare case of laryngotracheal chondrosarcoma in a patient with past history of radioiodine therapy for thyroid cancer
by: Gholamreza Mohajeri, et al.
Published: (2013-01-01)

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
by: S.M. Coelho, et al.
Published: (2011-01-01)

Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
by: S.M. Coelho, et al.
Published: (2011-01-01)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
by: Cristiane J. Gomes-Lima, et al.
Published: (2021-02-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE
by: L. M. Farkhutdinova
Published: (2018-06-01)

Radioiodine-induced oxidative stress in patients with differentiated thyroid carcinoma and effect of supplementation with vitamins C and E and selenium (antioxidants)
by: Pedro Weslley Rosário, et al.
Published: (2016-02-01)

In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation
by: Luis Felipe Zavala, et al.
Published: (2019-04-01)

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
by: Carla Colombo, et al.
Published: (2020-11-01)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
by: Chae Moon Hong, et al.
Published: (2017-10-01)

Autonomous Functioning Thyroid Nodule in a 4-year-old Male Child Treated with Radioiodine (I-131)
by: Abhishek Khare, et al.
Published: (2013-01-01)

Ultrasound Assessment of Autonomous Thyroid Nodules before and after Radioiodine Therapy Using Thyroid Imaging Reporting and Data System (TIRADS)
by: Simone Agnes Schenke, et al.
Published: (2020-12-01)

Salivary gland function in thyroid cancer patients with radioiodine administration history
by: Eva Krcalova, et al.
Published: (2020-09-01)

The history of radioiodine therapy beginnings
by: Pavel Olegovich Rumiantsev, et al.
Published: (2016-03-01)

Differentiated Thyroid Carcinoma and Late Onset of Lung Distant Metastasis. A Case Report
by: Alessandro Semprebene, et al.
Published: (2019-02-01)

ANTI-THYROGLOBULIN ANTIBODIES IN PATIENTS WITH AUTOIMMUNE THYROIDITIS DURING L-THYROXINE TREATMENT
by: O. A. Shashkova, et al.
Published: (2014-07-01)

ANTI-THYROGLOBULIN ANTIBODIES IN PATIENTS WITH AUTOIMMUNE THYROIDITIS DURING L-THYROXINE TREATMENT
by: O. A. Shashkova, et al.
Published: (2014-07-01)